A Phase I, Open Label, Randomized, 4-way Crossover Trial to Evaluate the Pharmacokinetics of TMC278 25mg and 50mg in the Presence of Omeprazole 20mg q.d., in Healthy Subjects.

Trial Profile

A Phase I, Open Label, Randomized, 4-way Crossover Trial to Evaluate the Pharmacokinetics of TMC278 25mg and 50mg in the Presence of Omeprazole 20mg q.d., in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2010

At a glance

  • Drugs Omeprazole; Rilpivirine
  • Indications Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; HIV infections; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 01 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top